Integra LifeSciences (IART) Gains After Q1 Beat, Supply Improvements

Integra LifeSciences (IART) shares rose 31% to $13.96 after the medical technology company reported first-quarter results that topped Wall Street expectations, driven by stronger tissue reconstruction demand, improved supply execution and cost controls. Management said margin gains were supported by a favorable product mix, tariff benefits and lower quality remediation costs. CEO Stuart Essig, recently reinstated, said quality and operational improvements helped restore more reliable product availability. Investors are watching the production ramp at the Braintree facility, the relaunch of SurgiMend, ongoing supply reliability and the effect of Medicare reimbursement changes on inpatient and outpatient wound care revenue. Progress in those areas will be key to whether Integra can sustain revenue growth and margin improvement.